..start with a cup of Baseline, heat up to its P value, remove from stove and divide by its N number, add a generous pinch of BS, coat in Ben Gay and voila!!......you have a STRUT WOMAC A number that is no better than SPRING study's number.
....he plays with numbers & semantics to confuse the less sophisticated. The bottom line is STRUT numbers WERE exceptional, 64% over baseline IS 64% over baseline, and there is nothing out there that even comes close to competing with Ampion's pain efficacy and duration of action.
It is highly likely that these results will be mirrored in the STRIDE trial. And while hack scientist BenGay may not see it, or want to see it, you can be sure that Pharma sees the value proposition here. Not too much longer for STRIDE results, which will end the conversation(if we don't have a deal beforehand)
...why don't you just go away until STRIDE results. Or maybe just call the company or speak with their largest shareholders and get a clue.
...company's line was that WOMC A scores of 55% to 60% would be a "home run", and scores north of 60% would be "unbelievable". Unprecedented pain relief at 20 weeks. Ampion will obsolete all the HA products. MM has stated that as soon as they get STRUT data they will start to have Pharma come in. I would expect similar results from STRIDE.
Wrong Wd-40, read the presentation from the Annual Meeting - primary endpoint is 20 weeks for WOMAC, but study extends to 24 weeks.
No, the death knell for the shorts would be AMPE declaring a special dividend from some of the upfront money from a deal with Pharma. I've heard MM mention such a thing. Obviously you need strong data and the deal first. I do know that MM HATES the shorts.
I hate to take the position of the Board Plague, but you have steadfastly refused to acknowledge the issue of naked shorting re. AMPE. Unless MM is just plain lying or wrong, there is a large & significant naked short position in AMPE, and naked shorting does manipulate the stock price.
Mr Chartmesister, I think you're full of BS.
...hopefully with successful STRUT data this all changes, as the shorts will be overwhelmed by institutional buying and volume. It is difficult to get a borrow on AMPE shares, so the shorts just create stock out of thin air and sell naked.
According to "Ben Gay/WD-40/Debbie Downer" Williams, our best hope is that MI Ampion shows some differentiation to MI Saline.
WD-40, you simply don't have a clue. No kidding, OAK is not an autoimmune disease - jt is talking about Ampion maybe one day competing with Humira, Embril or Remicade - all muiti $Billion drugs. Competing treatments for other joints? Not a miracle drug? Let's wait and see the WOMAC numbers, Ben Gay.